Lanifibranor is an indole sulfonamide derivative and a balanced pan-PPAR agonist that has demonstrated strong therapeutic potential in pre-clinical models of NAFLD/NASH [156]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.